Browse News
Filter News
Found 485,915 articles
-
Maybe timing is everything. On Aug. 28, 2017, Gilead acquired Kite for about $11.9B.
-
Shortly after Rhythm made its public debut on the Nasdaq Exchange, Pfizer has snapped up a small percentage of the company focused on treating rare genetic disorders that lead to obesity.
-
WalletHub recently examined the quarterly filings of hedge funds to determine which stocks they’re buying the most.
-
Vivek Ramaswamy's parent company, Roivant Sciences, inked a development deal with Astra.
-
Eli Lilly Looks Over Its Shoulder After Novo Nordisk Wins FDA Panel Backing for Diabetes Drug
10/19/2017
An advisory panel with the FDA gave a near unanimous support to Novo Nordisk's diabetes drug semaglutide, a long-acting GLP-1 analogue. -
Shares of Arcturus are up nearly 15 percent in Thursday morning trading after the company inked a collaboration agreement with Janssen Pharma to develop a hepatitis B drug program.
-
About 250 Pfizer employees will remain in the Memphis area after the pharma giant secured a partial tax freeze for 14 years from local governments that will save the company an estimated $5.3M in taxes.
-
EnteroMedics recently filed with the SEC that it had raised $61M in a new equity financing round. There were 13 anonymous investors.
-
Tyme's SM-88 Demonstrates Prolonged Overall Survival in Metastatic Cancer Patients Across Multiple Subgroups
10/19/2017
The subgroup analysis evaluated three common factors that can influence overall survival in oncology trials.
-
Prometic Receives Priority Review Status From Health Canada for Plasminogen (Ryplazim)
10/19/2017
Prometic today announced that Health Canada has granted priority review status for the NDS the company plans to file for its plasminogen replacement therapy (RyplazimTM) for the treatment of patients with plasminogen deficiency.
-
The company plans to expeditiously advance AMT-061 instead of AMT-060.
-
New Study Comparing Effectiveness of Alkermes' Extended-Release Naltrexone to Buprenorphine-Naloxone for Opioid Dependence Published in JAMA Psychiatry
10/19/2017
Results were published this week in the Journal of the American Medical Association Psychiatry.
-
BioMarin updated the investment community on the Company's development portfolio at R&D Day in New York.
-
NGM Bio Provides Update on NGM282 in NASH
10/19/2017
NGM Bio today provided an update on the development of NGM282, a compound in Phase 2 clinical testing for the treatment of NASH.
-
AOBiome Therapeutics Reports Positive Efficacy Results from Phase IIb Clinical Trial of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Acne Vulgaris
10/19/2017
AOBiome today announced positive efficacy and safety findings from the Phase 2b clinical trial of the Company's Ammonia Oxidizing Bacteria (AOB) product candidate for the treatment of mild-to-moderate acne vulgaris.
-
Corbus Pharmaceuticals Reports Positive Topline Results From Phase 2 Study In Rare Autoimmune Disease Dermatomyositis
10/19/2017
Corbus Pharmaceuticals Holdings announced positive topline results from its 16-week Phase II study of safety and efficacy of anabasum in dermatomyositis (“DM”).
-
OncoSec Presents Positive Phase II Data for ImmunoPulse IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder Melanoma Patients
10/19/2017
The data was presented today in an oral presentation at the 2017 9th World Congress of Melanoma.
-
OncoSNIPE Artificial Intelligence Project Officially Launched
10/19/2017
Oncodesign, a biopharmaceutical group specialized in precision medicine, and UNICANCER present the details of the OncoSNIPE project, which aims to develop and apply artificial intelligence techniques to cancer research.
-
Lycera Announces Advancement of Novel Immuno-Oncology Candidate LYC-55716 RORgamma Agonist into Phase IIa
10/19/2017
Lycera today announced the initiation of the Phase 2a portion of the company's Phase 1/2a ARGON study of its novel immuno-oncology therapeutic candidate, LYC-55716 is a first-in-class oral, selective retinoic acid-related orphan receptor-gamma (RORgamma) agonist, designed to reprogram the immune system in patients with advanced, relapsed or refractory solid tumors.
-
Revance Completes Patient Enrollment In Phase 2 Program For RT002 Injectable In The Management Of Plantar Fasciitis
10/19/2017
Revance Therapeutics announced it has completed enrollment of patients in the Company's Phase 2 program investigating the use of DaxibotulinumtoxinA for Injection (RT002) for the management of plantar fasciitis.